With overseas manufacturing sites in Germany and Italy, Aesica makes active ingredients and finished medicines for well-known drug companies and smaller biotech firms. In 2004 chief executive Robert Hardy led a buyout from BASF’s British drug-making business, backed by private equity firm LDC. In October last year, Silverfleet Capital invested in Aesica, replacing LDC. International sales to areas including mainland Europe and North America have grown 37% a year, from £80.6m in 2009 to £151.7m in 2011.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.